Development of an enzyme-linked immunosorbent assay for detection of cellular and in vivo LRRK2 S935 phosphorylation

scientific article published on 16 December 2012

Development of an enzyme-linked immunosorbent assay for detection of cellular and in vivo LRRK2 S935 phosphorylation is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.JPBA.2012.12.002
P932PMC publication ID4196644
P698PubMed publication ID23313773
P5875ResearchGate publication ID234122934

P50authorBart De StrooperQ4865062
Dario AlessiQ5222818
Jinwei ZhangQ47825457
Patrik VerstrekenQ28420142
P2093author name stringDiederik W Moechars
Guy Daneels
Kristof Van Kolen
Lore Delbroek
Raquel da Cunha
Wim Mandemakers
Kris Gevaert
Pieter-Jan De Bock
Liesbeth Steegmans
P2860cites workLRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in miceQ35288337
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.Q35780973
The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activityQ36154267
Brain Penetrant LRRK2 InhibitorQ36305876
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localizationQ36780383
Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in DrosophilaQ36891456
Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's diseaseQ37139305
Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questionsQ37225356
Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutantsQ39223630
Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibitionQ39457004
Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study.Q54690286
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activityQ22254785
LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosisQ24299176
Kinase activity of mutant LRRK2 mediates neuronal toxicityQ24303603
LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutationsQ24306239
Insight into the mode of action of the LRRK2 Y1699C pathogenic mutantQ24306788
The familial Parkinsonism gene LRRK2 regulates neurite process morphologyQ24317613
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localizationQ24339094
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathologyQ28131833
The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signalingQ28480459
Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylationQ28482925
Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's diseaseQ28586694
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control studyQ29614953
Kinase activity is required for the toxic effects of mutant LRRK2/dardarinQ29620478
Dynamic and redundant regulation of LRRK2 and LRRK1 expressionQ33307626
Identification of the autophosphorylation sites of LRRK2.Q33510233
Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesisQ33595218
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's diseaseQ34112588
Recent advances in the genetics of Parkinson's diseaseQ34189660
P921main subjectELISEAQ332126
P1104number of pages10
P304page(s)49-58
P577publication date2012-12-16
P1433published inJournal of Pharmaceutical and Biomedical AnalysisQ15752537
P1476titleDevelopment of an enzyme-linked immunosorbent assay for detection of cellular and in vivo LRRK2 S935 phosphorylation
P478volume76

Reverse relations

cites work (P2860)
Q37053959Decoding Parkinson's Disease Pathogenesis: The Role of Deregulated mRNA Translation
Q40188432In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2.
Q42372493Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker
Q47414771Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils
Q96953324LRRK2 Phosphorylation, More Than an Epiphenomenon
Q35170220Lack of correlation between the kinase activity of LRRK2 harboring kinase-modifying mutations and its phosphorylation at Ser910, 935, and Ser955.
Q39002226Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).
Q99238235Pharmacodynamic Biomarkers for Emerging LRRK2 Therapeutics
Q41163700Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation
Q21131229Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism
Q41579661Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells.

Search more.